Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

NCT00430534 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Epstein Barr Virus (EBV) Infection

Interventions

BIOLOGICAL: EBV vaccine (268664)

Sponsor

Henogen